Opsynvi experts: Single combo tablet likely to be easier for patients
As of April 15,Ā Opsynvi (macitentan and tadalafil) ā the first single-tablet treatment combination approved by the U.S. Food and Drug Administration (FDA) for pulmonary arterial hypertension (PAH) ā is available to eligible patients in the U.S. through a specialty pharmacy network. With its launch, PAH patients who…